Home > Frequently asked questions (FAQ): therapeutic use of psychedelic substances.

European Union Drugs Agency. (2024) Frequently asked questions (FAQ): therapeutic use of psychedelic substances.

[img]
Preview
PDF (FAQ therapeutic use of psychedelic substances - July 2024) - Published Version
1MB

External website: https://www.euda.europa.eu/publications/frequently...


Recent years have seen a growing public and clinical interest in the potential therapeutic use of a number of psychedelic substances, including some novel and little-known substances. A number of jurisdictions outside the EU have begun regulating the use of psychedelics for medical and therapeutic purposes, while significant commercial interest has arisen in this area, evidenced through the appearance of so-called ‘psychedelic retreats’ in a number of countries. An increasing number of clinical studies are exploring the potential of a range of psychedelic substances for different mental health conditions. Some research appears promising; however, generalising in this area is difficult, partly because of the large number of substances under review and partly because of the wide range of conditions that are being studied. Taken together, these developments have given rise to questions at the policy level relating to the risks associated with the increase in experimental use of these substances, their potential to cause harm, and appropriate policy responses. 

Repository Staff Only: item control page